493 results on '"Poli Van Creveldkliniek Medisch"'
Search Results
2. The importance and evolution of bleeding disorder registries
3. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
4. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders
5. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
6. The relevance of MRI findings in joints of persons with haemophilia: Insights from the last decade
7. Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortality
8. Perioperative platelet reactivity over time in patients undergoing vascular surgery: An observational pilot study
9. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B
10. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
11. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
12. Towards Personalized Treatment in Haemophilia: The Role of Genetic Factors in Iron and Heme Control to Identify Patients at Risk for Haemophilic Arthropathy
13. The RoxyScan is a novel measurement of red blood cell deformability under oxidative and shear stress
14. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
15. Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
16. Ultrasound in addition to clinical assessment of acute musculoskeletal complaints in bleeding disorders: impact on patient management
17. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry
18. Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single-arm, open-label study
19. Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
20. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies
21. Imlifidase for hematologists: Creating a therapeutic window in the presence of neutralizing alloantibodies
22. COVID-19 disease in patients with chronic neutropenia: The experience from the European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias
23. Navigating the challenges: a case report on managing a complicated postpartum course in type 3 von Willebrand disease with alloantibodies
24. Unravelling Facets of MECOM-Associated Syndrome: Somatic Genetic Rescue, Clonal Hematopoiesis and Phenotype Expansion
25. A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders
26. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
27. Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells
28. Prothrombin forced into an awkward position
29. Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobody
30. Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry
31. Targeted exome analysis in patients with rare bleeding disorders: data from the Rare Bleeding Disorders in the Netherlands study
32. Osmotic gradient ektacytometry – a novel diagnostic approach for neuroacanthocytosis syndromes
33. Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort
34. Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practice
35. Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis
36. Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias - pilot study protocol
37. Protection from bleeds during physical activity in people with haemophilia: the role of factor levels: a response to Nogami et al. (2023)
38. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
39. Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103] (Blood Reviews (2023) 61, (S0268960X23000644), (10.1016/j.blre.2023.101103))
40. Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency
41. “Antiphospholipid antibody solid phase–based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome”: reply
42. Letter in response to Bounaix et al. “Management of anticoagulation and factor XIII replacement in a patient with severe factor XIII deficiency and recurrent venous thromboembolic disease: case report and review of literature”
43. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement
44. Arthropathy on X-rays in 363 persons with hemophilia: long-term development, and impact of birth cohort and inhibitor status
45. A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease
46. Antiphospholipid antibody solid phase based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome
47. Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease
48. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease
49. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder: A systematic literature review
50. Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.